GROUP ONE TRADING, L.P. - KERYX BIOPHARMACEUTICALS INC ownership

KERYX BIOPHARMACEUTICALS INC's ticker is KERX and the CUSIP is 492515101. A total of 126 filers reported holding KERYX BIOPHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is 1.12 and the average weighting 0.4%.

Quarter-by-quarter ownership
GROUP ONE TRADING, L.P. ownership history of KERYX BIOPHARMACEUTICALS INC
ValueSharesWeighting
Q3 2018$23,000
-86.8%
6,876
-85.2%
0.00%
-100.0%
Q2 2018$174,000
-71.2%
46,322
-64.3%
0.00%
-75.0%
Q4 2017$604,000
-61.9%
129,913
-41.8%
0.00%
-71.4%
Q3 2017$1,584,000
+106.2%
223,115
+110.1%
0.01%
+75.0%
Q2 2017$768,000
-22.1%
106,203
-33.7%
0.01%
-27.3%
Q1 2017$986,000
-37.4%
160,132
-40.4%
0.01%
-26.7%
Q4 2016$1,575,000
+2.9%
268,727
-6.7%
0.02%
-11.8%
Q3 2016$1,530,000
+152.9%
288,069
+215.0%
0.02%
+142.9%
Q2 2016$605,000
-29.7%
91,444
-50.4%
0.01%
-41.7%
Q1 2016$860,000
+35.9%
184,178
+47.0%
0.01%
+71.4%
Q4 2015$633,000
+261.7%
125,288
+151.3%
0.01%
+250.0%
Q3 2015$175,000
-89.2%
49,849
-69.3%
0.00%
-91.3%
Q2 2015$1,621,000
+68.0%
162,421
+114.3%
0.02%
+53.3%
Q1 2015$965,000
-55.3%
75,783
-50.3%
0.02%
-54.5%
Q4 2014$2,158,000
+2564.2%
152,500
+2500.2%
0.03%
+3200.0%
Q3 2014$81,000
-97.6%
5,865
-97.4%
0.00%
-98.1%
Q2 2014$3,443,000
+2431.6%
223,879
+2712.6%
0.05%
+2550.0%
Q1 2014$136,000
-96.9%
7,960
-97.6%
0.00%
-97.0%
Q4 2013$4,353,000
+89.4%
336,153
+47.7%
0.07%
+50.0%
Q3 2013$2,298,000
+7.5%
227,528
-20.5%
0.04%
-17.0%
Q2 2013$2,138,000286,2220.05%
Other shareholders
KERYX BIOPHARMACEUTICALS INC shareholders Q4 2013
NameSharesValueWeighting ↓
VHCP Management, LLC 700,273$10,770,0005.76%
HARVEY CAPITAL MANAGEMENT INC 932,400$14,340,0005.13%
Camber Capital Management LP 3,000,000$46,140,0003.02%
Baupost Group 10,539,986$162,105,0002.64%
SECTORAL ASSET MANAGEMENT INC 3,741,656$57,547,0002.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,884,409$59,742,0002.40%
Knoll Capital Management, LLC 200,000$3,076,0001.37%
DAFNA Capital Management LLC 92,400$1,421,0001.35%
NORTHPOINTE CAPITAL LLC 892,011$13,719,0001.32%
Rhenman & Partners Asset Management AB 240,000$3,691,0001.10%
View complete list of KERYX BIOPHARMACEUTICALS INC shareholders